Dare Bioscience, Inc. cotiza a 0.75 USD y tiene una capitalización bursátil de $15M. En los últimos 12 meses ha facturado $1M con un margen de flujo de caja libre del -997.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-fr…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.20 | $-0.10 | $-0.28 |
| Estimado | $-0.30 | $-0.30 | $-0.42 | $-0.40 |
| Sorpresa | — | +33.3% | +76.2% | +30.0% |
| Métrica | DARE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 71.3% | 57.0% | +14.3% |
| Operating Margin | -1315.5% | -38.6% | -1276.9% |
| Net Margin | -1300.7% | -33.6% | -1267.1% |
| FCF Margin | -997.0% | -13.9% | -983.1% |
| ROE | -471.4% | -40.4% | -431.0% |
| ROA | -41.3% | -32.0% | -9.3% |
| Current Ratio | 1.14 | 2.84 | -1.70 |
| Debt / Equity | — | 0.28 | — |